This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday
Analysts downgraded Novo Nordisk, Chewy, NuScale Power and Atmos Energy, cutting price targets for three companies.
Stocks · News reference
Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40
Morgan Stanley analyst Thibault Boutherin downgrades Novo Nordisk (NYSE:NVO) from Equal-Weight to Underweight and maintains the price target from $40 to $40.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
China Approves Novo Nordisk's Wegovy As First And Only GLP-1 RA Treatment For MASH
-Reuters
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.